Survodutide vs Ozempic and Zepbound: What the New Phase 3 Trial Results Actually Show

A dual-receptor obesity drug has now cleared phase 3 testing, and the results are more nuanced than the early phase 2 data suggested. Survodutide — developed by Boehringer Ingelheim and Zealand Pharma — activates both the GLP-1 and glucagon receptors, a mechanism distinct from the GLP-1/GIP combination used by tirzepatide (Mounjaro, Zepbound). Three separate phase 3 trials reported results in 2026: one in adults with obesity, one in adults with obesity and type 2 diabetes, and one specifically in people with obesity and metabolic dysfunction-associated steatotic liver disease (MASLD) — the liver condition formerly known as NAFLD.

Here is what the phase 3 evidence actually shows, how it compares with already-approved drugs, and what remains unproven.

What Is Survodutide?

Survodutide is a dual GLP-1 and glucagon receptor agonist. That distinction matters. Currently approved GLP-1 drugs like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) work primarily by activating GLP-1 receptors in the gut and brain, which reduces appetite and slows gastric emptying. Tirzepatide adds GIP (glucose-dependent insulinotropic polypeptide) receptor activation, which appears to amplify weight loss further.

Survodutide takes a different second pathway. Instead of GIP, it activates glucagon receptors. Glucagon has historically been thought of as a hormone that raises blood sugar — the opposite of insulin. But at the doses used in survodutide’s trials, glucagon receptor activation increases fat burning in the liver and appears to raise energy expenditure, mobilising fat stores rather than only suppressing appetite. When combined with GLP-1’s appetite-suppressing effect, the intended result is a dual action: reduced calorie intake alongside increased fat oxidation, particularly in the liver.

What the Phase 3 Trials Found

Survodutide’s phase 3 programme, called SYNCHRONIZE, includes multiple separate trials. Three have reported results so far:

Note: these figures use the trial’s efficacy/treatment-regimen estimand reported in company and conference coverage; the full peer-reviewed tables in NEJM and the EASD presentation should be checked directly for exact per-dose breakdowns before citing a single number as “the” result.

Survodutide and Liver Fat: The SYNCHRONIZE-MASLD Trial

A separate 48-week phase 3 trial, SYNCHRONIZE-MASLD, enrolled adults with obesity or overweight who also had MASLD with inflammation or fibrosis (reported enrollment of 216-218 participants across sources). It was published in Nature Medicine in June 2026, alongside presentation at the American Diabetes Association’s 2026 Scientific Sessions. This is where survodutide’s results are most distinctive:

Separately, survodutide has received FDA Breakthrough Therapy Designation for non-cirrhotic MASH — a status granted to speed the review of drugs that show substantial improvement over existing therapy on preliminary evidence. This designation does not mean approval; it means the FDA has agreed to work with Boehringer Ingelheim on an expedited development and review pathway. Boehringer is now running two further phase 3 trials specifically in MASH with fibrosis — LIVERAGE and LIVERAGE-Cirrhosis — which are still recruiting/ongoing, including trial sites in India (Chandigarh, Hyderabad, Jaipur, New Delhi, and other cities), according to the current ClinicalTrials.gov registry entries.

How Survodutide Compares to Existing Drugs — Without Overstating It

It’s tempting to line up headline weight-loss percentages from different trials and declare a winner. That comparison is weaker than it looks, because these are separate trials with different populations, dosing, and durations — not a head-to-head study. With that caveat stated plainly:

• Semaglutide 2.4mg (Wegovy) produced roughly 15 percent body weight loss in its pivotal STEP 1 trial at 68 weeks.
• Tirzepatide 15mg (Zepbound) produced roughly 21 percent body weight loss in its pivotal SURMOUNT-1 trial at 72 weeks — the highest figure among this group.
• Survodutide (3.6mg/6.0mg) produced 12.2-13.0 percent body weight loss in SYNCHRONIZE-1 at 76 weeks.

On pure weight-loss magnitude, the phase 3 survodutide numbers are more modest than the phase 2 data (which reported up to 18.7 percent at a higher, 4.8mg dose not carried into phase 3) had suggested, and they trail tirzepatide’s pivotal result. This is a meaningful, honest correction to make: survodutide has not been shown, in like-for-like phase 3 data, to “beat” tirzepatide on weight loss alone, and its position relative to semaglutide is closer than earlier phase 2 figures implied.

Where survodutide’s phase 3 evidence is genuinely distinctive is the liver data above — the SYNCHRONIZE-MASLD trial’s liver-fat and visceral-fat results, combined with the FDA’s Breakthrough Therapy Designation for MASH, point to a drug whose strongest, best-supported case right now is for people with obesity who also have significant liver fat disease, not simply “a stronger weight-loss drug than what’s already approved.”

The Fatty Liver Disease (MASLD) Crisis in India

To understand why survodutide’s liver results matter so much for India specifically, it helps to look at India-specific prevalence data. The Phenome India cohort study — led by India’s Council of Scientific and Industrial Research (CSIR) and published in The Lancet Regional Health – Southeast Asia in 2026 — screened over 10,000 adults with FibroScan across 27 cities and found an age-adjusted MASLD prevalence of 38.9 percent, with significant liver fibrosis in 2.4 percent of adults screened. Other pooled Indian estimates range from roughly 28 percent in average-risk community populations to over 50 percent in high-risk groups and clinic-based diabetes populations, with urban prevalence running especially high.

MASLD progresses silently. Most people have no symptoms until the disease has advanced toward MASH or fibrosis. There is currently no approved pharmacological treatment specifically for MASLD in India — patients are advised lifestyle modification, but adherence is poor and progression continues in many. A drug that could directly address liver fat as part of a broader metabolic treatment programme would address a genuinely large unmet need — which is exactly why the SYNCHRONIZE-MASLD data and the MASH Breakthrough Therapy Designation are the more important story here, not the headline weight-loss number.

Side Effects and Safety: What the Phase 3 Data Add

The phase 3 safety profile is broadly consistent with other GLP-1-class drugs, but with a tolerability signal worth taking seriously rather than minimising. In SYNCHRONIZE-1, gastrointestinal adverse events (nausea, vomiting, diarrhoea, decreased appetite) occurred in 81 percent of participants on the 3.6mg dose and 90 percent on the 6.0mg dose, versus 48 percent on placebo — most mild to moderate and concentrated during dose escalation, consistent with the drug class.

The more clinically important number is discontinuation: roughly 24-25 percent of participants on survodutide stopped treatment because of an adverse event, compared with about 5.4 percent on placebo. Different sources report slightly different sub-figures depending on whether they isolate GI-specific discontinuations (reported as roughly 18-20 percent) or all-cause adverse-event discontinuations (roughly 24-25 percent) — but by either measure, this is a materially higher discontinuation rate than the phase 2 data implied, and higher than what’s typically reported for approved GLP-1 drugs at their standard doses. No deaths were reported in SYNCHRONIZE-1, and there was no signal of increased heart rate or worsening glycaemic control despite the glucagon-receptor component.

The honest summary: survodutide’s efficacy on both weight and liver fat is real and statistically confirmed in phase 3, but its tolerability — specifically the rate of people who stop taking it — remains a genuine open question that phase 3 data has, if anything, made more prominent rather than less.

Is Survodutide Approved? Is It Available in India?

No, on both counts, as of this update (October 2026). Survodutide has completed three reported phase 3 trials (SYNCHRONIZE-1, SYNCHRONIZE-2, SYNCHRONIZE-MASLD), but no regulatory agency — not the US FDA, not Europe’s EMA, not India’s CDSCO — has approved it for any indication. Available reporting has not confirmed a formal new drug application (NDA) submission date; third-party estimates of a possible 2027 approval and 2027-2028 launch exist, but these are analyst projections, not confirmed company or regulatory timelines, and should be treated accordingly.

In India specifically, survodutide is present only as a clinical trial — the LIVERAGE and LIVERAGE-Cirrhosis MASH trials have active or planned sites in cities including Chandigarh, Hyderabad, Jaipur, and New Delhi, and India is also listed as a site for the ongoing SYNCHRONIZE cardiovascular outcomes trial. India’s CDSCO expert committees have reviewed and cleared trial-protocol amendments for survodutide (in 2024 and 2025), which is routine clinical-trial oversight — it is not a marketing approval and should not be confused with one. For comparison, CDSCO approved a generic version of semaglutide for the Indian market in February 2026; that approval is for a different, already-established drug and has no bearing on survodutide’s regulatory status.

Anyone encountering a website, telehealth service, or “research peptide” vendor offering survodutide for purchase or self-administration should treat this as a significant red flag: the drug is not legally available for prescription or purchase anywhere, and anything sold under this name outside an authorised clinical trial carries unknown manufacturing, purity, and safety risk.

The Next Wave: How Survodutide Fits in the Obesity Pipeline

Survodutide is not the only next-generation obesity drug in late-stage development. Retatrutide — a triple-receptor agonist targeting GLP-1, GIP, and glucagon simultaneously — produced roughly 24 percent body weight loss in its own phase 2 trial and is now in phase 3. Orforglipron, an oral GLP-1 pill (not an injection), is also in phase 3 and could materially improve access for patients with needle aversion. The competitive landscape is evolving quickly, and the next few years will likely bring approval of multiple new agents with different receptor profiles, delivery methods, and advantages for specific patient subgroups.

Survodutide’s clearest niche in this landscape, based on the phase 3 evidence now available, is patients with significant metabolic liver disease (MASLD/MASH) alongside obesity — rather than patients looking purely for the largest possible weight-loss number, where tirzepatide’s pivotal data currently leads.

What Patients Can Do While Waiting

For people managing obesity or fatty liver disease right now, the most evidence-backed steps do not require waiting for survodutide’s approval. For weight management, current GLP-1 options — semaglutide and tirzepatide — are already available in India for patients who can access them, and bariatric surgery remains a highly effective option for appropriate candidates. For MASLD, the most impactful intervention remains a minimum 7 to 10 percent reduction in body weight through dietary change and physical activity, which has been shown to produce histological improvement in MASH in randomised trials.

Natural metabolic support through berberine — a plant-derived AMPK activator with evidence for improving insulin sensitivity and reducing liver fat — has also shown modest but real benefits in multiple clinical trials for metabolic syndrome and MASLD. It is not a substitute for drug treatment but represents a practical addition to lifestyle measures for patients who are not yet candidates for, or do not have access to, pharmacological treatment.

Frequently Asked Questions

Dr. Ajit Kumar’s clinical perspective

The Bottom Line

Survodutide’s phase 3 results confirm it works — on both body weight and, especially, liver fat — but they also correct the record on how well it works relative to earlier phase 2 projections and to tirzepatide specifically. On pure weight loss, it is not clearly ahead of already-approved drugs; on liver fat reduction in MASLD, including a 61 percent liver-fat normalisation rate and an FDA Breakthrough Therapy Designation for MASH, its evidence is genuinely among the strongest reported for any single drug in this space.

It is not available yet — no regulator has approved it, and when it does become available, cost, access, and its real-world tolerability (roughly a quarter of phase 3 participants discontinued due to side effects) will all be significant factors. Given the scale of the MASLD problem in India — an age-adjusted prevalence of 38.9 percent in the 2026 Phenome India cohort study — the stakes in how this drug’s liver-specific trials (LIVERAGE, LIVERAGE-Cirrhosis) read out are particularly high for the South Asian population.

For a comprehensive overview of the current GLP-1 landscape and how these drugs compare to bariatric surgery, read our guide on GLP-1 drugs reshaping obesity treatment.

For more health research summaries and clinical updates, visit medimadad.com.